With an emphasis on diagnostics tools, the independently funded C-Path Institute aims to have a significant role in helping the FDA better oversee innovation. Mark Ratner reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Funding for accelerating drug development initiative critical
Janet Woodcock discusses the role of the FDA in improving pharma productivity
Web links
Rights and permissions
About this article
Cite this article
Ratner, M. Looking for solid ground along the Critical Path. Nat Biotechnol 24, 885–887 (2006). https://doi.org/10.1038/nbt0806-885
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0806-885
This article is cited by
-
Privatizing biomedical research—a 'third way'
Nature Biotechnology (2008)
-
News in brief
Nature Biotechnology (2007)
-
Drug companies accused of stalling tailored therapies
Nature Medicine (2006)